

---

## 1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER

---

### 1.1 Product identifier

**Product name** ZYCORTAL 25MG/ML PROLONGED RELEASE SUSPENSION FOR INJECTION FOR DOGS (NZ)  
**Synonyms** ZYCORTAL

### 1.2 Uses and uses advised against

**Uses** DOG TREATMENT • VETERINARY APPLICATIONS • VETERINARY USE  
For use as replacement therapy for the mineralocorticoid deficit in Dogs with primary hypoadrenocorticism (Addison's disease).

**Uses advised against** Do not use in case of hypersensitivity to the active substance or to any of the excipient(s).

### 1.3 Details of the supplier of the product

**Supplier name** DECHRA VETERINARY PRODUCTS NZ LTD  
**Address** PO Box 1604, Paraparaumu Beach, 5252, NEW ZEALAND  
**Telephone** 0800 473 838  
**Email** [info.nz@dechra.com](mailto:info.nz@dechra.com)  
**Website** <http://www.dechra.co.nz/>

### 1.4 Emergency telephone numbers

**Emergency** 0800 764 766 (National Poisons Centre NZ)

---

## 2. HAZARDS IDENTIFICATION

---

### 2.1 Classification of the substance or mixture

HAZARDOUS ACCORDING TO NZ ENVIRONMENTAL PROTECTION AUTHORITY CRITERIA

#### Physical Hazards

Not classified as a Physical Hazard

#### Health Hazards

Toxic to Reproduction: Category 2

#### Environmental Hazards

Not classified as an Environmental Hazard

### 2.2 GHS Label elements

**Signal word** WARNING

#### Pictograms



#### Hazard statements

H361 Suspected of damaging fertility or the unborn child.

#### Prevention statements

P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection.

**PRODUCT NAME ZYCORTAL 25MG/ML PROLONGED RELEASE SUSPENSION FOR INJECTION FOR DOGS (NZ)**

**Response statements**

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

**Storage statements**

P405 Store locked up.

**Disposal statements**

P501 Dispose of contents/container in accordance with relevant regulations.

**2.3 Other hazards**

May produce an allergic reaction.

---

### 3. COMPOSITION/ INFORMATION ON INGREDIENTS

---

**3.1 Substances / Mixtures**

Ingredient	CAS Number	EC Number	Content
DESOXYCORTONE PIVALATE	808-48-0	212-366-0	2.5%
3-METHYL-4-CHLOROPHENOL	59-50-7	200-431-6	<0.1%
NON HAZARDOUS INGREDIENTS	Not Available	Not Available	Remainder

---

### 4. FIRST AID MEASURES

---

**4.1 Description of first aid measures**

**Eye** If in eyes, hold eyelids apart and flush continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre, a doctor, or for at least 15 minutes.

**Inhalation** If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.

**Skin** If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre or a doctor.

**Ingestion** For advice, contact the National Poisons Centre on 0800 764 766 (0800 POISON) or +643 479 7248 or a doctor (at once). Rinse mouth out with water and give plenty of water to drink.

**First aid facilities** Eye wash facilities and a hand wash basin are recommended.

**4.2 Most important symptoms and effects, both acute and delayed**

See Section 11 for more detailed information on health effects and symptoms.

**4.3 Immediate medical attention and special treatment needed**

Treat symptomatically.

---

### 5. FIRE FIGHTING MEASURES

---

**5.1 Extinguishing media**

Use an extinguishing agent suitable for the surrounding fire.

**5.2 Special hazards arising from the substance or mixture**

Non flammable. May evolve carbon oxides and hydrocarbons when heated to decomposition.

**5.3 Advice for firefighters**

Treat as per requirements for surrounding fires. Evacuate area and contact emergency services. Remain upwind and notify those downwind of hazard. Wear full protective equipment including Self Contained Breathing Apparatus (SCBA) when combating fire. Use waterfog to cool intact containers and nearby storage areas.

**5.4 Hazchem code**

None allocated.

---

### 6. ACCIDENTAL RELEASE MEASURES

---

**6.1 Personal precautions, protective equipment and emergency procedures**

Wear Personal Protective Equipment (PPE) as detailed in section 8 of the SDS.

**PRODUCT NAME ZYCORTAL 25MG/ML PROLONGED RELEASE SUSPENSION FOR INJECTION FOR DOGS (NZ)**

**6.2 Environmental precautions**

Prevent product from entering drains and waterways.

**6.3 Methods of cleaning up**

Contain spillage, then cover / absorb spill with non-combustible absorbent material (vermiculite, sand, or similar), collect and place in suitable containers for disposal.

**6.4 Reference to other sections**

See Sections 8 and 13 for exposure controls and disposal.

---

**7. HANDLING AND STORAGE**

---

**7.1 Precautions for safe handling**

Before use carefully read the product label. Use of safe work practices are recommended to avoid eye or skin contact and inhalation. Observe good personal hygiene, including washing hands before eating. Prohibit eating, drinking and smoking in contaminated areas.

**7.2 Conditions for safe storage, including any incompatibilities**

Store in a cool, dry, well marked area, removed from incompatible substances, foodstuffs and other drugs. Storage areas and containers should be clearly marked for drug holding, protected from light, freezing or physical damage and tightly sealed when not in use. Keep out of reach of children. Store below 25°C (air conditioning). Keep the vial in the outer carton in order to protect from light. Do not freeze.

**7.3 Specific end uses**

No information provided.

---

**8. EXPOSURE CONTROLS / PERSONAL PROTECTION**

---

**8.1 Control parameters**

**Exposure standards**

No exposure standards have been entered for this product.

**Biological limits**

No biological limit values have been entered for this product.

**8.2 Exposure controls**

**Engineering controls** Avoid inhalation. Use in well ventilated areas.

**PPE**

<b>Eye / Face</b>	Wear splash-proof goggles.
<b>Hands</b>	Wear PVC or rubber gloves.
<b>Body</b>	Wear coveralls.
<b>Respiratory</b>	Where an inhalation risk exists, wear a Type A (Organic vapour) respirator.



---

**9. PHYSICAL AND CHEMICAL PROPERTIES**

---

**9.1 Information on basic physical and chemical properties**

<b>Appearance</b>	OPAQUE WHITE LIQUID
<b>Odour</b>	SLIGHT ODOUR
<b>Flammability</b>	NON FLAMMABLE
<b>Flash point</b>	NOT RELEVANT
<b>Boiling point</b>	NOT AVAILABLE
<b>Melting point</b>	NOT AVAILABLE
<b>Evaporation rate</b>	NOT AVAILABLE
<b>pH</b>	NOT AVAILABLE
<b>Vapour density</b>	NOT AVAILABLE

**PRODUCT NAME ZYCORTAL 25MG/ML PROLONGED RELEASE SUSPENSION FOR INJECTION FOR DOGS (NZ)**

**9.1 Information on basic physical and chemical properties**

Relative density	NOT AVAILABLE
Solubility (water)	INSOLUBLE
Vapour pressure	NOT AVAILABLE
Upper explosion limit	NOT RELEVANT
Lower explosion limit	NOT RELEVANT
Partition coefficient	NOT AVAILABLE
Autoignition temperature	NOT AVAILABLE
Decomposition temperature	NOT AVAILABLE
Viscosity	NOT AVAILABLE
Explosive properties	NOT AVAILABLE
Oxidising properties	NOT AVAILABLE
Odour threshold	NOT AVAILABLE

---

**10. STABILITY AND REACTIVITY**

---

**10.1 Reactivity**

Carefully review all information provided in sections 10.2 to 10.6.

**10.2 Chemical stability**

Stable under recommended conditions of storage.

**10.3 Possibility of hazardous reactions**

Polymerization is not expected to occur.

**10.4 Conditions to avoid**

Avoid heat, sparks, open flames and other ignition sources. Light sensitive.

**10.5 Incompatible materials**

Incompatible with oxidising agents (e.g. hypochlorites), acids (e.g. nitric acid) and alkalis (e.g. sodium hydroxide).

**10.6 Hazardous decomposition products**

May evolve carbon oxides and hydrocarbons when heated to decomposition.

---

**11. TOXICOLOGICAL INFORMATION**

---

**11.1 Information on toxicological effects**

**Acute toxicity** This product is used in veterinary applications. Use safe work practices to avoid eye contact, prolonged skin contact and ingestion. Refer to medical doctor/specialist for advice regarding adverse side effects.

**Information available for the ingredients:**

Ingredient	Oral LD50	Dermal LD50	Inhalation LC50
3-METHYL-4-CHLOROPHENOL	1830 mg/kg (rat)	--	--

<b>Skin</b>	Contact may result in irritation, redness, pain and rash.
<b>Eye</b>	Contact may result in irritation, lacrimation, pain and redness.
<b>Sensitisation</b>	Contains an ingredient that is known to cause skin sensitisation, at levels below that required for classification. Not classified as causing respiratory sensitisation.
<b>Mutagenicity</b>	Not classified as a mutagen.
<b>Carcinogenicity</b>	Not classified as a carcinogen.
<b>Reproductive</b>	Suspected of damaging fertility or the unborn child.
<b>STOT - single exposure</b>	Not classified as causing organ damage from single exposure. However, high level exposure may result in headache, nausea and respiratory tract irritation.
<b>STOT - repeated exposure</b>	Not classified as causing organ damage from repeated exposure.
<b>Aspiration</b>	Not classified as causing aspiration.

---

**12. ECOLOGICAL INFORMATION**

---

**PRODUCT NAME ZYCORTAL 25MG/ML PROLONGED RELEASE SUSPENSION FOR INJECTION FOR DOGS (NZ)**

**12.1 Toxicity**

No information provided.

**12.2 Persistence and degradability**

No information provided.

**12.3 Bioaccumulative potential**

No information provided.

**12.4 Mobility in soil**

No information provided.

**12.5 Other adverse effects**

No information provided.

---

**13. DISPOSAL CONSIDERATIONS**

---

**13.1 Waste treatment methods**

**Waste disposal** Return to manufacturer/supplier where possible. For small amounts, bury in approved landfill site. Contact the manufacturer/supplier for additional information (if required).

**Legislation** Dispose of in accordance with relevant local legislation.

---

**14. TRANSPORT INFORMATION**

---

**NOT CLASSIFIED AS A DANGEROUS GOOD ACCORDING TO LAND TRANSPORT RULE: DANGEROUS GOODS 2005; NZS 5433:2012, UN, IMDG OR IATA**

	LAND TRANSPORT (NZS 5433)	SEA TRANSPORT (IMDG / IMO)	AIR TRANSPORT (IATA / ICAO)
<b>14.1 UN Number</b>	None allocated.	None allocated.	None allocated.
<b>14.2 Proper Shipping Name</b>	None allocated.	None allocated.	None allocated.
<b>14.3 Transport hazard class</b>	None allocated.	None allocated.	None allocated.
<b>14.4 Packing Group</b>	None allocated.	None allocated.	None allocated.

**14.5 Environmental hazards**

Not a Marine Pollutant.

**14.6 Special precautions for user**

**Hazchem code** None allocated.

---

**15. REGULATORY INFORMATION**

---

**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

**Approval code** HSR100757

**Group standard** Veterinary Medicines (Limited Pack Size, Finished Dose) Group Standard 2020

**ACVM Number** A011422

**Inventory listings** **AUSTRALIA: AIIC (Australian Inventory of Industrial Chemicals)**  
All components are listed on AIIC, or are exempt.  
**NEW ZEALAND: NZIoC (New Zealand Inventory of Chemicals)**  
All components are listed on the NZIoC inventory, or are exempt.

---

**16. OTHER INFORMATION**

---

**Additional information**

**PRODUCT NAME ZYCORTAL 25MG/ML PROLONGED RELEASE SUSPENSION FOR INJECTION FOR DOGS (NZ)**

**WORKPLACE CONTROLS AND PRACTICES:** Unless a less toxic chemical can be substituted for a hazardous substance, **ENGINEERING CONTROLS** are the most effective way of reducing exposure. The best protection is to enclose operations and/or provide local exhaust ventilation at the site of chemical release. Isolating operations can also reduce exposure. Using respirators or protective equipment is less effective than the controls mentioned above, but is sometimes necessary.

**RESPIRATORS:** In general the use of respirators should be limited and engineering controls employed to avoid exposure. If respiratory equipment must be worn ensure correct respirator selection and training is undertaken. Remember that some respirators may be extremely uncomfortable when used for long periods. The use of air powered or air supplied respirators should be considered where prolonged or repeated use is necessary.

**PERSONAL PROTECTIVE EQUIPMENT GUIDELINES:**

The recommendation for protective equipment contained within this report is provided as a guide only. Factors such as form of product, method of application, working environment, quantity used, product concentration and the availability of engineering controls should be considered before final selection of personal protective equipment is made.

**HEALTH EFFECTS FROM EXPOSURE:**

It should be noted that the effects from exposure to this product will depend on several factors including: form of product; frequency and duration of use; quantity used; effectiveness of control measures; protective equipment used and method of application. Given that it is impractical to prepare a report which would encompass all possible scenarios, it is anticipated that users will assess the risks and apply control methods where appropriate.

**Abbreviations**

ACGIH	American Conference of Governmental Industrial Hygienists
CAS #	Chemical Abstract Service number - used to uniquely identify chemical compounds
CCID	Chemical Classification and Information Database (HSNO)
CNS	Central Nervous System
EC No.	EC No - European Community Number
EMS	Emergency Schedules (Emergency Procedures for Ships Carrying Dangerous Goods)
EPA	Environmental Protection Authority [New Zealand]
GHS	Globally Harmonized System
HSNO	Hazardous Substances and New Organisms
IARC	International Agency for Research on Cancer
LC50	Lethal Concentration, 50% / Median Lethal Concentration
LD50	Lethal Dose, 50% / Median Lethal Dose
mg/m <sup>3</sup>	Milligrams per Cubic Metre
OEL	Occupational Exposure Limit
pH	relates to hydrogen ion concentration using a scale of 0 (high acidic) to 14 (highly alkaline).
ppm	Parts Per Million
STEL	Short-Term Exposure Limit
STOT-RE	Specific target organ toxicity (repeated exposure)
STOT-SE	Specific target organ toxicity (single exposure)
TLV	Threshold Limit Value
TWA	Time Weighted Average

**Report status**

This document has been compiled by RMT on behalf of the manufacturer, importer or supplier of the product and serves as their Safety Data Sheet ('SDS').

It is based on information concerning the product which has been provided to RMT by the manufacturer, importer or supplier or obtained from third party sources and is believed to represent the current state of knowledge as to the appropriate safety and handling precautions for the product at the time of issue. Further clarification regarding any aspect of the product should be obtained directly from the manufacturer, importer or supplier.

While RMT has taken all due care to include accurate and up-to-date information in this SDS, it does not provide any warranty as to accuracy or completeness. As far as lawfully possible, RMT accepts no liability for any loss, injury or damage (including consequential loss) which may be suffered or incurred by any person as a consequence of their reliance on the information contained in this SDS.

**PRODUCT NAME ZYCORTAL 25MG/ML PROLONGED RELEASE SUSPENSION FOR INJECTION FOR DOGS (NZ)**

**Prepared by**

Risk Management Technologies  
5 Ventnor Ave, West Perth  
Western Australia 6005  
Phone: +61 8 9322 1711  
Fax: +61 8 9322 1794  
Email: [info@rmt.com.au](mailto:info@rmt.com.au)  
Web: [www.rmtglobal.com](http://www.rmtglobal.com)

**[ End of SDS ]**